NASDAQ$SGMT

Sagimet Biosciences Inc-A · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$2M

No prior period
EPS (adj)

-$0.35

Previous: $6.69K-100.0%
Capital Expenditures

$0.00

No prior period
Free Cash Flow

-$6.35M

No prior period
Net Income

-$6.35M

Previous: -$7.47M+14.9%
Operating Income

-$7.45M

Previous: -$7.69M+3.0%
Gross Profit

$1.97M

No prior period
Cash & Equivalents

$102M

Previous: $2.23M+4466.9%
Total Assets

$103M

No prior period
R&D Expense

$4.96M

No prior period
Stock-Based Comp

$1.86M

Previous: $389K+376.9%

Revenue & EPS history

Sagimet Biosciences · Revenue · Quarterly

$2M

Q3 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-3.0%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+17.0%

Avg return

30 days after

43%

6 / 14 earnings

Positive

+16.0%

Q4 2023

Best reaction

-21.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-0.2%-10.2%-16.5%
Q3 2025-12.5%-11.3%-29.4%
Q1 2025+6.6%+7.1%+118.6%
Q4 2024+3.5%-7.0%-30.5%
Q3 2024-21.4%-26.7%-27.1%
Q2 2024+3.8%+6.0%+39.8%
Q1 2024+8.4%+8.2%-5.5%
Q1 2023+8.4%+8.2%-5.5%
Q4 2023+16.0%+20.2%-7.5%
Q3 2022-2.5%+14.5%+113.9%
Q3 2023-2.5%+14.5%+113.9%
Q2 2022-16.3%-5.1%-8.6%
Q2 2023-16.3%-5.1%-8.6%
Q4 2022-16.3%-5.1%-8.6%
Q1 2022
Q1 2021
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro